An Integrated Data Analysis of mRNA, miRNA and Signaling Pathways in Pancreatic Cancer

Sohrabi, Ehsan; Rezaie, Ehsan; Heiat, Mohammad; Sefidi-Heris, Yousef

doi:10.1007/s10528-021-10062-x

Cited by 28 publications

(25 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SLC family is associated with the proliferation and migration of tumors, IL-17 signaling [49], and has also been shown to drive tumor metastasis [50]. Other genes among the top 20, including ATF3, TGFBR1, and EGFR, are associated with the ECM-receptor interaction and IL-17 signaling pathways [51]. The PPI analysis suggests that ferroptosisrelated genes are associated with the progression of TSCC and further confirmed that ferroptosis-related genes might influence prognosis through ECMreceptor interaction and IL-17 signaling.…”

Section: Discussionmentioning

confidence: 99%

Identification of ferroptosis‐related genes as potential biomarkers of tongue squamous cell carcinoma using an integrated bioinformatics approach

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of ferroptosis‐related genes as potential biomarkers of tongue squamous cell carcinoma using an integrated bioinformatics approach

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The recognition of tumor markers is necessary for the development of targeted therapy approaches [42,43]. Here, HCC tumor markers are presented, some of which are used in immunotoxin immunotherapy, and some of them could be good candidates in this regard (Table 1).…”

Section: Hcc Tumor Markersmentioning

confidence: 99%

Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect

Heiat

Yeganeh

Alavian

et al. 2021

Toxins

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. Therefore, fighting against such cancer is reasonable. Chemotherapy drugs are sometimes inefficient and often accompanied by undesirable side effects for patients. On the other hand, the emergence of chemoresistant HCC emphasizes the need for a new high-efficiency treatment strategy. Immunotoxins are armed and rigorous targeting agents that can purposefully kill cancer cells. Unlike traditional chemotherapeutics, immunotoxins because of targeted toxicity, insignificant cross-resistance, easy production, and other favorable properties can be ideal candidates against HCC. In this review, the characteristics of proper HCC-specific biomarkers for immunotoxin targeting were dissected. After that, the first to last immunotoxins developed for the treatment of liver cancer were discussed. So, by reviewing the strengths and weaknesses of these immunotoxins, we attempted to provide keynotes for designing an optimal immunotoxin against HCC.

show abstract

“…The development of anticancer drugs against specific antigens of cancer cells is one of the new attractive methods for researchers to treat cancers [6][7][8]. As such, in line with this approach, the first, and probably the main, milestone is discovering an appropriated specific antigen as a cancer cell marker [9,10]. GPC3 is a glycophosphatidylinositol (GPI)anchored cell surface heparan sulfate proteoglycan that is expressed during the early stage of cancer [11], but not in normal adult tissues [12].…”

Section: Introductionmentioning

confidence: 99%

DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study

Yeganeh

Heiat

Kieliszek

et al. 2021

Toxins

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the high-metastatic types of cancer, and metastasis occurs in one-third of patients with HCC. To maintain the effectiveness of drug compounds on cancer cells and minimize their side effects on normal cells, it is important to use new approaches for overcoming malignancies. Immunotoxins (ITs), an example of such a new approach, are protein-structured compounds consisting of toxic and binding moieties which can specifically bind to cancer cells and efficiently induce cell death. Here, we design and scrutinize a novel immunotoxin against an oncofetal marker on HCC cells. We applied a truncated diphtheria toxin (DT389) without binding domain as a toxin moiety to be fused with a humanized YP7 scFv against a high-expressed Glypican-3 (GPC3) antigen on the surface of HCC cells. Cytotoxic effects of this IT were investigated on HepG2 (GPC3+) and SkBr3 (GPC3−) cell lines as positive- and negative-expressed GPC3 antigens. The dissociation constant (Kd) was calculated 11.39 nM and 18.02 nM for IT and YP7 scfv, respectively, whereas only IT showed toxic effects on the HepG2 cell line, and decreased cell viability (IC50 = 848.2 ng/mL). Changing morphology (up to 85%), cell cycle arrest at G2 phase (up to 13%), increasing intracellular reactive oxygen species (ROSs) (up to 50%), inducing apoptosis (up to 38% for apoptosis and 23% for necrosis), and an almost complete inhibition of cell movement were other effects of immunotoxin treatment on HepG2 cells, not on SkBr3 cell line. These promising results reveal that this new recombinant immunotoxin can be considered as an option as an HCC inhibitor. However, more extensive studies are needed to accomplish this concept.

show abstract

An Integrated Data Analysis of mRNA, miRNA and Signaling Pathways in Pancreatic Cancer

Cited by 28 publications

References 102 publications

Identification of ferroptosis‐related genes as potential biomarkers of tongue squamous cell carcinoma using an integrated bioinformatics approach

Identification of ferroptosis‐related genes as potential biomarkers of tongue squamous cell carcinoma using an integrated bioinformatics approach

Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect

DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study

Contact Info

Product

Resources

About